Anzeige
Meldung des Tages: Tiger Gold meldet massive Goldtreffer – rückt Quinchía jetzt in die Weltklasse-Liga?

Tiziana Life Sciences ADR News

Aktie
WKN:  A2PTNF ISIN:  US88875G1013
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Index-Zuordnung
-

Tiziana Life Sciences ADR News

16.04.26 - GlobeNewswire
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID ...
14.04.26 - GlobeNewswire
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, ...
01.04.26 - GlobeNewswire
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal ...
25.02.26 - GlobeNewswire
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal ...
20.01.26 - GlobeNewswire
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, ...
16.01.26 - GlobeNewswire
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal ...
16.01.26 - GlobeNewswire
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, ...
09.01.26 - GlobeNewswire
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal ...
29.12.25 - GlobeNewswire
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-​years cumulative exposure FDA denial of Sanofi’s tolebrutinib for nrSPMS shows need for safe ...
19.12.25 - GlobeNewswire
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
17.12.25 - GlobeNewswire
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
17.12.25 - GlobeNewswire
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-​Controlled Phase 2 Trial Builds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients ...
15.12.25 - GlobeNewswire
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
15.12.25 - GlobeNewswire
Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
12.12.25 - GlobeNewswire
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial
First Patient Expected to be Dosed Next Week with Intranasal Foralumab PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi ® ...
02.12.25 - GlobeNewswire
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
25.11.25 - GlobeNewswire
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
13.11.25 - GlobeNewswire
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
29.10.25 - GlobeNewswire
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
30.09.25 - GlobeNewswire
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...

Newssuche

Videos

newspaper
16.04.26 +0,41%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »